Novartis ($NVS) was last year's biggest R&D spender in the pharma industry. Now, the company is warning U.K. officials that, unless they change their ways, Novartis will be spending less and less of its research billions in that country. Report
| Tuesday, April 14th | 1pm ET / 10am PT | Presented by: Rho
At first glance, the TMF reference model seems daunting, especially for smaller companies. In this webinar, Kristen Snipes and Missy Lavinder share tips and tricks for making the process manageable based on their own recent experience implementing the model. Register today!
FiercePharma is the pharma industry's daily monitor, with a special focus on pharmaceutical company news and the market development of FDA approved products. Join 150,000+ pharma industry leaders who get FiercePharma via daily email. Click here to get your free weekly email briefing today!